# Deborah Schrag

Source: https://onco.cc/people/deb-schrag/  
OnCo record `deb-schrag` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led PATHFINDER, the first prospective study of a multi-cancer blood test in practice, and the PROSPECT rectal cancer trial.

## Summary

Deborah Schrag was principal investigator of PATHFINDER, the first prospective study to return Galleri multi-cancer early detection results to participants and their doctors, which showed a cancer signal in about 1% of people and a positive predictive value near 40%, and of PROSPECT, the Alliance trial showing FOLFOX can replace pelvic radiotherapy for many rectal cancers. She chairs medicine at MSKCC and leads pragmatic outcomes research.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: early-detection; mced; colorectal
- Role: Chair, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Specialisms: Multi-cancer early detection; Colorectal cancer; Health services research; Pragmatic trials

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Deborah_Schrag
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Schrag%20D%5BAuthor%5D%20PATHFINDER%20OR%20PROSPECT

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- technologies: [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Galleri](https://onco.cc/drugs/galleri/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [NHS-Galleri](https://onco.cc/trials/nhs-galleri/), [PATHFINDER 2](https://onco.cc/trials/pathfinder-2/)
- key papers: [PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms](https://onco.cc/key-papers/paper-pathfinder-lancet-2023/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/)

---
JSON: https://onco.cc/api/v1/entities/deb-schrag.json